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Abstract
Background: The thalassemia syndromes are classified according to the globin chain or chains whose production
is affected. β-thalassemias are caused by point mutations or, more rarely, deletions or insertions of a few nucleotides in
the β-globin gene or its immediate flanking sequences. These mutations interfere with the gene function either at the
transcriptional, translational or posttranslational level.
Methods: Two cases of Polish patients with hereditary hemolytic anemia suspected of thalassemia were studied. DNA
sequencing and mRNA quantification were performed. Stable human cell lines which express wild-type HBB
and mutated versions were used to verify that detected mutation are responsible for mRNA degradation.
Results: We identified two different frameshift mutations positioned in the third exon of HBB. Both patients
harboring these mutations present the clinical phenotype of thalassemia intermedia and showed dominant
pattern of inheritance. In both cases the mutations do not generate premature stop codon. Instead, slightly
longer protein with unnatural C-terminus could be produced. Interestingly, although detected mutations are
not expected to induce NMD, the mutant version of mRNA is not detectable. Restoring of the open reading
frame brought back the RNA to that of the wild-type level.
Conclusion: Our results show that a lack of natural stop codon due to the frameshift in exon 3 of β-globin
gene causes rapid degradation of its mRNA and indicate existence of novel surveillance pathway.
Keywords: β- thalassemia, Frameshift mutations, Gene expression, mRNA degradation
Background
β-thalassemias are one of the most common monogenic
diseases in the world. They are common in tropical and
subtropical regions where they provide protection
against malaria, but are rather rare in Northern Europe.
Some limited cases have been described in the indige-
nous British, Irish, Breton [1, 2], Scandinavian [3],
German [4] and Polish populations [5]. The total annual
prevalence of symptomatic individuals is estimated at 1
in 10,000 in the European Union [6].
Hemoglobin disorders comprise two different groups,
structural hemoglobin defects and the thalassemias,
where the abundance of a globin chain is decreased. The
classical recessive forms of β-thalassemia lead to a re-
duced production of normal β-globin chains. In contrast,
dominantly inherited β-thalassemia is caused by some
rare mutations resulting in the synthesis of extremely
unstable β-globin [7].
The HBB gene encoding β-globin, spans 1.6 kb and
comprises three exons, with the first and third one con-
taining mainly noncoding sequences of the5’ and 3’ UTRs.
378 different β-thalassemia mutations have now been
characterized worldwide [8]. In many cases β-thalassemia
mutations generate premature stop codons which lead
to degradation of mutated RNA by RNA surveillance
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mechanism called nonsense-mediated mRNA decay
(NMD). Activation of NMD for the β-globin mRNA de-
pends on the position of the nonsense mutations: muta-
tions that reside at least 50 nt5’ to the last intron/exon
junction direct the affected mRNA for rapid decay,
while those occurring in the 3’part of the gene usually
escape NMD [9]. In very rare cases disappearance of
mRNA for β-globin in which mutations are present at
the 3’ end of the mature mRNA has been described
[10]. RNA surveillance mechanism responsible for this
phenomenon remains to be determined.
The aim of the present study was to look for muta-
tions in the β-globin gene in patients with hereditary
hemolytic anemia suspected of thalassemia. Two cases
(Patient 1 and Patient 2) were investigated and various
frameshift mutations (c.375_376insCCAGT and c.349del)
located in the third exon have been identified. In both
patients the level of β-globin mRNA was substantially
lower than in healthy subjects. By mimicking CCAGT
insertion in cultured human cells we established the
molecular mechanism by which the identified genetic
changes diminish β-globin expression. Here, we show
that newly identified mutations direct the HBB mRNA




Patient 1: A 6-year-old boy, born to non-consanguineous
parents has been under medical supervision since birth
because of hemolytic anemia of unknown etiology. He
presented with splenomegaly and xanthoderma. Occasio-
nally, the patient needed red blood cells (RBCs) transfu-
sions. Laboratory tests indicated profound anemia and
hyperbilirubinemia. Congenital dyserythropoietic anemias,
hereditary spherocytosis and anemias due to deficiency
of red cell enzymes were excluded. HbF and HbA2
levels were elevated and β-thalassemia was diagnosed.
Compatible clinical presentation of hemolytic anemia
was observed in mother and younger sister of the pro-
band. His mother had splenectomy in childhood with-
out significant improvement of anemia but she hasn’t
need RBC transfusion. The results of blood tests of all
subjects are presented in Table 1.
Patient 2: A 10-year-old boy with hemolytic anemia
and hyperbilirubinemia of unknown etiology, born to
healthy non-consanguineous parents, has been observed
since birth. Initially, hereditary spherocytosis was diag-
nosed, based on the assessment of peripheral blood
smear. Occasionally, he needed RBC transfusions. At the
age of 8, splenectomy was performed but without benefi-
cial effect. Hemoglobin electrophoresis revealed elevated
level of fetal hemoglobin (4%) and hemoglobin A2
(4.3%), consistently with β-thalassemia diagnosis. There
was no family history of blood diseases.
Both patients were Caucasians of Polish origin. The
patients' parents gave informed consent to the study.
The study protocol has been approved by the Ethical
Committee of the Medical University of Warsaw. The
study was conducted according to principles laid out in
the Declaration of Helsinki.
RNA isolation, cDNA synthesis and determination of
mRNA levels
Total RNA was isolated from peripheral blood samples
using the PAXgene Blood RNA Kit (QIAGEN, Hilden,
Germany). cDNA was amplified with the use of primers
encompassing the coding sequence from exon 2 to
3’UTR. qPCR amplification was performed using a
LightCycler1.5 and LightCyclerFastStart DNA Master
SYBR Green I (Roche Diagnostics GmbH, Germany).
mRNA quantification of the β-globin genes was car-
ried out using real-time PCR. The Pfaffl model [11] and
the relative expression software tool (REST-384©)were
used to estimate the relative mRNA level of the β-globin
gene in the analyzed patients (compared with 20 healthy
individuals). Data normalization was carried out against
the transcript of the gene for EMP55 (erythrocyte mem-
brane protein p55).
DNA isolation and amplification
Genomic DNA was isolated from peripheral blood using
the MagNA Pure Compact Nucleic Acid Isolation Kit I
(Roche Diagnostics GmbH, Germany). Polymerase
chain reaction (PCR) was used to amplify the promoter
region, entire coding sequence and surrounding se-
quences of the β–globin gene. DNA fragments gene-
rated by PCR amplification were sequenced directly as
previously described [5]. Primer sequences are given in
Additional file 1: Table S1.
Analysis of XmnI polymorphism
XmnI (Fermentas, Vilnius, Lithuania) was used to verify
the presence of the XmnI-Gγ polymorphism [12].
DNA cloning and site-directed mutagenesis
DNA cloning was performed using standard methods.
HBB was amplified using RSZ394 (gtcggtaccccatggtg
catctgactcctg) and RSZ396 (gacctcgagttccctttttagtaaaata
ttcag) primers and DNA isolated from human 293 cells
as a template. Amplified DNA fragment was cloned into
pcDNA5FRT/TO vector (Invitrogen Carlsbad, CA, USA)
digested with Acc65I and XhoI to give plasmid pRS478.
Standard site-directed mutagenesis of pRS478 was per-
formed to introduce the mutation identified in patient 1
(pPO9) or the mutation together with an additional
nucleotide restoring the reading frame (pPO10). The
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following primers were used for mutagenesis: RSZ533
(gcaaagaattcaccccaccagtccagtgcaggctgcctatcag) and RSZ534
(ctgataggcagcctgcactggactggtggggtgaattctttgc) (to get pPO9)
and RSZ535 (gcaaagaattcaccccaccagtccagttgcaggctgcctat
cag) and RSZ536 (ctgataggcagcctgcaactggactggtggggtgaattc
tttgc) (to get pPO10).
Cell culture and establishing of stable cell lines
Cells were cultured in DMEM medium (Invitrogen) sup-
plemented with 10% FBS (Invitrogen) under standard
conditions (37 °C, 5% CO2). Stable transfected cell lines
were obtained from human 293 TRex-FlpIn cells using a
procedure described previously [13]. Expression of trans-
genes was induced with tetracycline (25 ng/ml).
RNA isolation and northern blotting
Total RNA was isolated with TriReagent (Sigma, Steinheim,
Germany) according to manufacturer’s recommendation.
Northern blotting was performed as previously [13]. The
primers used to prepare the probe were RSZ413 (gcagg
ctgctggtggtcta) and OPE16 (agccaggccatcactaaag).
Results
Initially we have quantified levels of globin mRNAs in
both patients which revealed a decreased β-globin tran-
script level by more than 50% in the investigated
patients and elevated levels of γ- and δ-globin compared
to the control group (Table 2).
In Patient 2 both γ - and δ -globin mRNAs were sub-
stantially more abundant than in controls, while in
Patient 1 only γ -globin mRNA was up-regulated mar-
kedly and δ-globin one showed a modest increase
(Table 2). Additionally, members of the Patient 1 family
presented greatly elevated HbF levels (Table 1). One of
the most significant genetic factors associated with high
HbF is XmnI polymorphism at position −158 upstream
of the Gγ-globin gene [14]. We therefore analysed the
XmnI polymorphism (Table 1), finding the −158 (C→T)
transition in one allele in the Patient 1 patient and his
sister. Their mother was homozygous for the XmnI poly-
morphism (T/T). Patient 2 was homozygous for the −158
C variant, in accordance with his only moderate increased
HbF level.
In order to identify disease-causing mutations of ana-
lyzed patients, their β-globin genes were specifically
amplified by PCR and subsequently sequenced. In both
patients we found heterozygous mutations in the exon 3
(Fig. 1a, b): in Patient 1 an insertion of five nucleotides
(c.375_376insCCAGT) and in Patient 2 a single nucleo-
tide deletion (c.349del). Both these frameshift mutations
change position of the stop codon. As a result slightly
longer open reading frames are produced. The families
of the probands were also tested for the presence of those
mutations. The c.375_376insCCAGT mutation was found
in the Patient’s 1 sister and mother. For Patient 2, only his
brother was available for the study and showed no muta-
tions in the HBB gene. The presence of mutations in the
investigated DNA samples was confirmed by independent
sequencing of the second strand.
To determine whether the mutated alleles are tran-
scribed, we reverse-transcribed region of interest and
sequenced the obtained cDNAs. Only the non-mutated
sequences were obtained for the both patients, indica-
ting the absence of mRNA encoded by the mutated
alleles. This could in principle result from rapid degra-
dation of the aberrant transcript or from lack of tran-
scription of the alleles. The latter seems unlikely, since
no addition mutations in the 5’ flank or 5’ part of the
gene were detected. Two mutations of the β-globin gene
reported here reside in the 5’ part of exon 3 and they
Table 2 Relative mRNA levels of globin genes
α-globin β-globin γ-globin δ-globin
Patient 1 0.94 (0.001) 0.46 (0.002) 90.89 (0.001) 4.28 (0.003)
Patient 2 1.42 (0.444) 0.37 (0.130) 44.25 (0.003) 44.29 (0.001)
p-values are given in brackets
Table 1 Hematologic parameters and molecular data
Family 1 Family 2
Patient 1 Sister of Patient 1 Mother of Patient 1 Patient 2 Brother of Patient 2
Age (years) 6 1.2 38 10 2
RBC (10^6/uL) 2.7 3.4 2.6 2.9 4.7
Hb (g/dL) 6.2 8.7 7.7 7.4 12.4
MCV (fL) 74 80.7 93 90.4 79.4
RDW (%) 34.4 21.3 26.9 35.8 14.3
Retics (% of RBC) 22.60 N.D. 15.83 11.43 1.92
HbA2 (%) 3.2 2.2 4.05 4.3 3.4
HbF (%) 9.5 22.5 12.9 4.0 2.1
XmnI polymorphism +/− +/− +/+ −/− N.D.
β-globin mutation c.375_376 insCCAGT/βN c.375_376 insCCAGT/βN c.375_376 insCCAGT/βN c.349 delC/βN βN/ βN
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both remove the native stop codon at position 147 and
create a novel one at positions 159 (Patient 1) or 157
(Patient 2) (Fig. 1c).
We considered three possible mechanisms which
could be responsible for the observed low steady-state
levels of the mutated HBB mRNA. The mutations could
somehow affect transcription of the gene, splicing or the
mutated HBB mRNA could be degraded rapidly by RNA
surveillance. Because, mutations are within a coding
region we found the first possibility to be very un-
likely. In order to analyse the effect of mutations on
splicing and stability we focused on the Patient 1 case
(c.375_376insCCAGT) and constructed three stable
human cell lines expressing in an inducible manner
wild-type HBB, its mutated version, or a variant con-
taining the original Patient 1 mutation followed by an
additional thymidine which restored the reading frame
(Fig. 2a). An incorrect position of the termination
codon may lead to RNA surveillance response [13],
thus restoring the original reading frame of HBB
mRNA should rescue the transcript stability. On the
other hand if Patient 1 mutation affects processing the
restoration of the original open reading frame should
not rescue the phenotype. Expression of the trans-
genes was induced with tetracycline and the levels of
corresponding RNAs were analyzed by northern blot-
ting. In agreement with the results for the patient’s
blood samples we found that the c.375_376insCCAGT
insertion decreases the level of HBB RNA in comparison
to the wild-type HBB (Fig. 2b), however, no effect on
splicing was observed. Importantly, the restoring of the
original reading frame with the additional nucleotide
brought back the RNA to the level to that observed for
the wild-type gene (Fig. 2b). The same results were ob-
served for four independent sets of samples. For all the
analyzed versions of HBB we observed two RNA species
of different lengths. Importantly, the level of both species
followed the same pattern of changes. These two species
could result from alternative transcription termination
and/or could reflect different of poly(A) tails. Regardless
of the nature of the two HBB mRNA species, these
results clearly show that frameshift caused by the
c.375_376insCCAGT insertion, but not the insertion
itself, activates an RNA degradation without affecting
pre-mRNA processing.
Discussion
RNA degradation plays an essential role in ensuring that
only fully functional RNA molecules become translated
by disposing of aberrant ones that are often mature but
dysfunctional. Their expression at the protein level could
disturb cellular functioning. Truncated or too long poly-
peptide chains could titer out other proteins, form in-
active complexes, misfold and aggregate or otherwise
hamper to the cell. Although numerous mechanisms do
exist for the disposal of aberrant polypeptides, they
could easily become overwhelmed by excessive pro-
duction of their substrates. Thus, defective RNA mo-
lecules, which are often mature but dysfunctional,
need to be degraded rapidly by variety of RNA sur-
veillance pathways [15].
Some cases of β-thalassemias are caused by mutations
in the HBB gene which introducing a premature stop
codon inducing nonsense mediated RNA decay. It has
been reported that NMD-promoting mutations located
in exon 1 or 2 of β-globin gene subject the trans-
cripts to rapid degradation [16]. Such mutations are
associated with mild anemia or even are symptomless.
In contrast, mutations in the terminal exon 3 escape
NMD and therefore can have a dominant-negative
effect [17]. In general, mutations that result in the
production of elongated or truncated globin chain
manifest in the heterozygous state with a thalassemia
intermedia phenotype, frequently associated with the
accumulation of inclusion bodies in peripheral eryth-
rocytes. They occur sporadically and show a dominant
transmission pattern. In most cases, protein analysis
fails to detect the abnormal Hb, presumably owing to
its high instability [1].
In our study we identified two different frameshift
mutations positioned in the third exon of HBB. Both
patients harboring these mutations present the clini-
cal phenotype of thalassemia intermedia and showed
Fig. 1 Novel exon 3 mutations in β-globin gene (a) DNA and cDNA
sequences analysis of Patients 1 and 2 (b) Alignment of DNA
sequences of normal and mutated β-globin genes from codon
114 to codon 126. (c) Amino acid sequences of C-termini of
normal β-globin (wt) and hypothetical β-chains starting from
last codon of exon 2
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dominant pattern of inheritance. In both cases the
mutations do not generate premature stop codon. Instead,
slightly longer protein with unnatural C-terminus could
be produced. Interestingly, although mutations of Patient
1 and Patient 2 are not expected to induce NMD, the
mutant version of mRNA is not detectable. For one of
these mutations, experiments using reporters in 293 cell
lines confirmed the degradation of the mutated transcript.
Furthermore, restoring of the origin reading frame stabi-
lized the transcript, which suggested that the destruction
of the wild type HBB reading frame was crucial for the
degradation of the defective mRNAs.
Our understanding of the mechanisms controlling
RNA quality is limited [18], and the degradation of the
mutated β-globin transcripts reported here cannot be
explained by any of the current NMD models. Few re-
ports have presented well documented mRNA depletion
in thalassemic hemoglobinopathies due to mutations in
the third exon. Grosso et al. [10] described a single- nu-
cleotide mutation in exon 3 of the β-globin gene respon-
sible for decreased mRNA levels and a β-thalassemic
defect. Musollimo et al. [19] reported that codon 105 +
AGCT mutation reduced the level of the abnormal
mRNA, which was found present only in trace amounts
and could not be translated into a functional β-chain.
According to the Globin Gene Server (http://globin.c-
se.psu.edu/) the majority of frameshift mutations in the
exon 3 at codons 108–141 do not produce a Hb variant
detectable by electrophoresis, chromatography, or stabil-
ity tests. In contrast, missense mutations downstream of
codon 141 produce abnormal Hb. It seems likely that
additional factors could bind to specific sequences crea-
ted by the frameshift mutations to facilitate their identi-
fication and consequent mRNA degradation. It seems
that effect of a given mutation, besides other factors, also
depends on its position within the HBB gene. This
phenomenon is currently unclear.
Conclusion
The two mutations described have add new information
regarding degradation of mutated β-globin mRNA and
thus could facilitate the deciphering of the underlying
mechanism. In particular, we have shown that moving
the STOP codon by as few as twelve codons downstream
suffices to destabilize the HBB mRNA.
Additional file
Additional file 1: Table S1. Sequences of the primers. (DOCX 13 kb)
Fig. 2 Restoring of original open reading frame rescues of transgene-encoded HBB mRNA. a Schema of HBB transgenes (b) Northern blot analysis of
HBB mRNA encoded by transgenes. RNA (2 μg per sample) isolated from parental 293 cells and their stable transgenic derivatives was resolved by size
using gel electrophoresis, transferred to membrane and HBB transcripts were detected using radiolabeled probe complementary to exon 2.
Lower panels shows RNA methylene blue staining as a loading control. RNA from 4 independent sets of experiments was analyzed. Numbers
at the bottom show relative level of the shorter HBB mRNA isoform. Signal from 18S rRNA was used for normalization. For a given experiment
wild-type sample was regarded as 1
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